Alkermes plc.
corporate_fare Company Profile
Alkermes plc. (NASDAQ:ALKS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for ALKS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for ALKS spans 8-K, 10-Q, 8-K/A, DEF 14A.
Recent high-impact activity:
- Alkermes Settles Teva LYBALVI Patent Suit; Generic Entry Delayed to November 2039
- Alkermes 10-Q: Q3 Revenue Up 22% to $480M, but Nine-Month Swing to $49.7M Loss
- Alkermes Posts Q3 2026 Results, Call Set for 8:00 a.m. ET
- Alkermes' ALKS 7290 Shows Clinically Meaningful ADHD Symptom Improvement in Phase 1b
- Alkermes Details $8M Equity Package for Incoming CEO Blair Jackson, Adds President Title and Board Seat
Financial Snapshot
Short Interest & Short Volume
11.25 days to coverFINRA reported short interest of 19,647,994 shares in ALKS as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 11.3 days to cover at its recent average daily volume. On November 20, 2026, 67.0% of ALKS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.